198 related articles for article (PubMed ID: 11196189)
1. Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase.
Khare PD; Shao-Xi L; Kuroki M; Hirose Y; Arakawa F; Nakamura K; Tomita Y; Kuroki M
Cancer Res; 2001 Jan; 61(1):370-5. PubMed ID: 11196189
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy in cancer via use of a retrovector having a tumor specificity and expressing inducible nitric oxide synthase.
Kuroki M
Methods Mol Biol; 2004; 279():201-11. PubMed ID: 15199247
[TBL] [Abstract][Full Text] [Related]
3. Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA.
Kuroki M; Arakawa F; Khare PD; Kuroki M; Liao S; Matsumoto H; Abe H; Imakiire T
Anticancer Res; 2000; 20(6A):4067-71. PubMed ID: 11131674
[TBL] [Abstract][Full Text] [Related]
4. Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene.
Khare PD; Liao S; Hirose Y; Kuroki M; Fujimura S; Yamauchi Y; Miyajima-Uchida H; Kuroki M
Anticancer Res; 2002; 22(4):2443-6. PubMed ID: 12174941
[TBL] [Abstract][Full Text] [Related]
5. Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody.
Konishi H; Ochiya T; Chester KA; Begent RH; Muto T; Sugimura T; Terada M
Hum Gene Ther; 1998 Jan; 9(2):235-48. PubMed ID: 9472783
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.
Crittenden M; Gough M; Chester J; Kottke T; Thompson J; Ruchatz A; Clackson T; Cosset FL; Chong H; Diaz RM; Harrington K; Alvarez Vallina L; Vile R
Cancer Res; 2003 Jun; 63(12):3173-80. PubMed ID: 12810645
[TBL] [Abstract][Full Text] [Related]
7. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
8. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
9. Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells.
Ojala K; Mottershead DG; Suokko A; Oker-Blom C
Biochem Biophys Res Commun; 2001 Jun; 284(3):777-84. PubMed ID: 11396970
[TBL] [Abstract][Full Text] [Related]
10. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles.
Schnierle BS; Moritz D; Jeschke M; Groner B
Gene Ther; 1996 Apr; 3(4):334-42. PubMed ID: 8732165
[TBL] [Abstract][Full Text] [Related]
11. Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein.
Liao S; Khare PD; Arakawa F; Kuroki M; Hirose Y; Fujimura S; Tomita Y; Kuroki M
Anticancer Res; 2001; 21(3B):1673-80. PubMed ID: 11497246
[TBL] [Abstract][Full Text] [Related]
12. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
[TBL] [Abstract][Full Text] [Related]
13. Toward targeted killing of tumor-specific antigen-producing cancer cells by retrovirus displaying a single chain variable fragment antibody.
Konishi H; Ochiya T; Muto T; Sugimura T; Terada M
Adv Exp Med Biol; 1998; 451():405-10. PubMed ID: 10026903
[No Abstract] [Full Text] [Related]
14. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
15. A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells.
Shibaguchi H; Luo NX; Kuroki M; Zhao J; Huang J; Hachimine K; Kinugasa T; Kuroki M
Anticancer Res; 2006; 26(6A):4067-72. PubMed ID: 17195459
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-specific gene transfer with retroviral vectors displaying single-chain antibody.
Tang Y; Li Y; Qian G
Chin Med J (Engl); 2002 Jul; 115(7):1064-9. PubMed ID: 12150744
[TBL] [Abstract][Full Text] [Related]
17. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model.
Ueda K; Iwahashi M; Nakamori M; Nakamura M; Matsuura I; Yamaue H; Tanimura H
Cancer Res; 2001 Aug; 61(16):6158-62. PubMed ID: 11507067
[TBL] [Abstract][Full Text] [Related]
19. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
20. Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors.
Chowdhury S; Chester KA; Bridgewater J; Collins MK; Martin F
Mol Ther; 2004 Jan; 9(1):85-92. PubMed ID: 14741781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
